Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent
The EMA is finally set to approve Pfizer's targeted anticancer Mylotarg for use in acute myeloid leukemia. The company also received opinions for Bosulif and Sutent.
You may also be interested in...
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.
Seven new drugs were approved in the EU in the March-April period this year: TiGenix/Takeda's Alofisel, BioCryst's Alpivab, Chiesi's Lamzede, AstraZeneca's Lokelma, Pfizer's Mylotarg, GSK's Shingrix and MSD's Steglatro.
Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.